
CTSO — Cytosorbents Crp
NASDAQ · Healthcare · Medical Devices
$0.34
-$0.00 (-0.59%)
Cytosorbents Crp (CTSO) is a medical devices company listed on NASDAQ. It is led by Phillip P. Chan M.D., Ph.D., based in 305 College Road East, Princeton, NJ, United States, 08540, with about 129 employees. Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform in the United States, Germany, and internationally. Its flagship product, CytoSorb, is an extracorporeal blood purification cartridge to reduce cytokine storms in common critical illnesses, bilirubin in liver failure, myoglobin in trauma and critical illnesses, and inflammatory mediators and blood thinners in cardiac surgery applications, as well as to remove antithrombotic drugs and inflammatory mediators in cardiothoracic surgery applications. The company also develops DrugSorb-ATR antithrombotic removal system, an investigational device to reduce the severity of perioperative bleeding in high-risk surgery due to blood thinning drugs; ECOS-300CY to reduce cytokines and other inflammatory mediators when used in an ex vivo organ perfusion system; VetResQ, a broad-spectrum blood purification adsorber for the treatment of septic shock, toxic shock syndrome, toxin-mediated diseases, pancreatitis, trauma, liver failure, heat stroke, and lung injury in animals; and PuriFi, an advanced hemoperfusion pump for blood purification therapies. In addition, it develops HemoDefend-BGA, a blood purification technology platform to reduce anti-A and anti-B antibodies in plasma and whole blood. The company was formerly known as MedaSorb Technologies Corporation and changed its name to Cytosorbents Corporation in May 2010. Cytosorbents Corporation was founded in 1997 and is headquartered in Princeton, New Jersey.
Net income was -$2.7M. CTSO currently screens at market cap $28.8M.
Use this CTSO page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the CTSO quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the CTSO SEC filings page. Lician reads the product cache first so this HTML stays unique to Cytosorbents Crp even when a live quote feed is slow.
About Cytosorbents Crp
Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform in the United States, Germany, and internationally. Its flagship product, CytoSorb, is an extracorporeal blood purification cartridge to reduce cytokine storms in common critical illnesses, bilirubin in liver failure, myoglobin in trauma and critical illnesses, and inflammatory mediators and blood thinners in cardiac surgery applications, as well as to remove antithrombotic drugs and inflammatory mediators in cardiothoracic surgery applications. The company also develops DrugSorb-ATR antithrombotic removal system, an investigational device to reduce the severity of perioperative bleeding in high-risk surgery due to blood thinning drugs; ECOS-300CY to reduce cytokines and other inflammatory mediators when used in an ex vivo organ perfusion system; VetResQ, a broad-spectrum blood purification adsorber for the treatment of septic shock, toxic shock syndrome, toxin-mediated diseases, pancreatitis, trauma, liver failure, heat stroke, and lung injury in animals; and PuriFi, an advanced hemoperfusion pump for blood purification therapies. In addition, it develops HemoDefend-BGA, a blood purification technology platform to reduce anti-A and anti-B antibodies in plasma and whole blood. The company was formerly known as MedaSorb Technologies Corporation and changed its name to Cytosorbents Corporation in May 2010. Cytosorbents Corporation was founded in 1997 and is headquartered in Princeton, New Jersey.
CTSO Key Statistics
Market Cap
$28.82M
Volume
123,039
Previous Close
$0.37
Day Range
$0.35 – $0.39
EPS
-$0.38
Revenue
$0.00
Net Income
-$20.72M
Gross Profit
$0.00
Free Cash Flow
$0.00
Employees
129
CTSO Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 |
|---|---|---|
| Revenue | $0.00 | $0.00 |
| Cost of Revenue | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 |
| Net Income | -$20.72M | -$29.25M |
| EPS (Diluted) | -$0.38 | -$0.12 |
Total Assets
$47.37M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$3.28M
Operating Cash Flow
-$14.43M
Free Cash Flow
$0.00
Cytosorbents Crp Company Information
- CEO & Director
- Phillip P. Chan M.D., Ph.D.
- Headquarters
- 305 College Road East, Princeton, NJ, United States, 08540
- Website
- www.cytosorbents.com
- Phone
- 732 329 8885
- IPO / Founded
- 2013-11-07
- Sector
- Healthcare
- Industry
- Medical Devices